Boston Scientific (NYSE:BSX) Price Target Cut to $45.00 by Analysts at Wells Fargo & Company

Boston Scientific (NYSE:BSX) had its price target cut by investment analysts at Wells Fargo & Company from $48.00 to $45.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 6.51% from the stock’s current price.

BSX has been the topic of several other reports. Mizuho set a $50.00 price target on shares of Boston Scientific in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Boston Scientific in a report on Friday, October 2nd. Robert W. Baird raised their price target on Boston Scientific from $50.00 to $51.00 and gave the stock an “outperform” rating in a report on Thursday. Jefferies Financial Group lowered Boston Scientific from a “buy” rating to a “hold” rating and set a $46.00 price target on the stock. in a report on Wednesday. Finally, The Goldman Sachs Group lowered their target price on Boston Scientific from $71.00 to $57.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $63.50.

Boston Scientific Trading Down 0.4%

Shares of BSX traded down $0.18 during trading on Thursday, reaching $42.25. 3,187,582 shares of the company traded hands, compared to its average volume of 18,595,738. Boston Scientific has a twelve month low of $39.57 and a twelve month high of $105.65. The stock has a market cap of $61.23 billion, a PE ratio of 17.09, a price-to-earnings-growth ratio of 1.10 and a beta of 0.58. The stock has a 50-day simple moving average of $45.12 and a 200-day simple moving average of $57.43. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.07 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. Boston Scientific’s revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.75 EPS. On average, analysts anticipate that Boston Scientific will post 3.21 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney bought 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David C. Habiger purchased 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 194,522 shares of company stock valued at $9,385,210 over the last quarter. Company insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

A number of institutional investors have recently added to or reduced their stakes in the stock. Avantax Planning Partners Inc. lifted its holdings in shares of Boston Scientific by 4.0% in the first quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock valued at $329,000 after purchasing an additional 201 shares in the last quarter. WPG Advisers LLC boosted its stake in shares of Boston Scientific by 11.9% during the first quarter. WPG Advisers LLC now owns 1,916 shares of the medical equipment provider’s stock valued at $120,000 after acquiring an additional 203 shares during the last quarter. Natural Investments LLC boosted its stake in shares of Boston Scientific by 1.3% during the second quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock valued at $685,000 after acquiring an additional 206 shares during the last quarter. 180 Wealth Advisors LLC increased its position in Boston Scientific by 3.6% during the 1st quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock worth $406,000 after purchasing an additional 223 shares in the last quarter. Finally, MGO One Seven LLC increased its position in Boston Scientific by 1.9% during the 3rd quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock worth $614,000 after purchasing an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter revenue of $5.138 billion, ahead of the $5.07 billion consensus estimate, while adjusted EPS of $0.73 matched expectations. Revenue increased approximately 1.5% year over year. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Management reiterated its long-term growth strategy, including a potential recovery cycle toward 2027 and expansion through 2030. The company also reported progress on the Elite AF clinical trial and new FDA clearances. Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance
• Positive Sentiment: Several analysts still see upside: Robert W. Baird raised its price target to $51 and maintained an “outperform” rating, while BTIG and Needham retained “buy” ratings despite lowering their targets. Recent insider activity also showed purchases by executives.
• Neutral Sentiment: Analyst sentiment has become more cautious. Oppenheimer downgraded BSX to “market perform,” and JPMorgan cut its rating to “neutral” with a $46 price target, reflecting increased near-term uncertainty.
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by approximately $150 million and continues to affect operations, customer activity and the pace of recovery.
• Negative Sentiment: Boston Scientific lowered its full-year 2026 outlook to roughly 4.25% reported sales growth and adjusted EPS of $3.16–$3.18. Fourth-quarter adjusted EPS guidance of $0.77–$0.79 fell short of expectations, while sales are expected to decline 1%–3% year over year. Boston Scientific Crashes As Cybersecurity Attack Weighs On Guide
• Negative Sentiment: Investors are also concerned about contracting margins, weaker heart-device demand and challenging pricing conditions in China, which management indicated could make 2027 difficult.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.